Some studies have shown that the incidence of brain metastases in lung adenocarcinoma patients with EGFR mutations is slightly higher than that in patients with wild-type EGFR, with an approximate incidence rate of 60% (7–9), indicating that lung adenocarcinoma patients with EGFR mutations may be more prone to developing brain metastases. The gene discussed is EGFR; the disease is lung adenocarcinoma.